ARYx Therapeutics, Inc.
6300 Dumbarton Circle
Fremont,
CA 94555
United States - Map
Phone: 510-585-2200
Fax: 510-585-2202
Web Site: http://www.aryx.com
| ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. The company's products in Phase II clinical trials include ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of patients with atrial fibrillation. Its preclinical development stage product comprises ATI-9242 for the treatment of schizophrenia and other psychiatric disorders. In addition, the company's late stage discovery programs consist of ATI-20,000 and ATI-24,000, which focuses on metabolic and gastrointestinal disorders. ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul Goddard Ph.D., 58
Chairman and Chief Exec. Officer |
N/A
| N/A | Dr. Peter G. Milner M.D., 52
Co-Founder, Pres of R&D |
N/A
| N/A | Dr. Pascal Druzgala Ph.D., 53
Co-Founder, Chief Scientific Officer and Sr. VP |
N/A
| N/A | Mr. John W. Varian , 49
Chief Operating Officer and Chief Financial Officer |
N/A
| N/A | Mr. David Nagler , 55
VP of Corp. Affairs and Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.47% Nasdaq 
0.01 (0.16%) 
Profile
